The independent platform for news, articles and advice for professionals in laboratory medicine

Gyros Protein Technologies introduces new reagents for immunogenicity assessment

Gyros Protein Technologies, a provider of peptide synthesisers and reagents and a pioneer in automated nanolitre-scale immunoassays, has announced the introduction of Gyrolab Generic Cyno Anti-Drug Antibodies (ADA) Kit Reagents, for the detection of circulating immune complexes of human IgG with cyno anti-human IgG.

The new ready-to-use kit reagents streamline pre-clinical development of antibody-based therapeutics, enabling immunogenicity screening of drug candidates without the need for drug-specific ADA assay development.

The new kit expedites bioanalysis by removing the need for assay development and optimisation across molecules to provide robust, reproducible, reliable data from nanolitre sample volumes. This is beneficial when ADA assessment is evaluated in pre-clinical animal models where sample volume may be limited.

Detecting and monitoring ADA is essential throughout drug development, in particular during the discovery stage, where multiple early-stage candidates are evaluated in parallel. During non-clinical studies, ADA monitoring is critical in understanding unexpected clearance profiles and safety or efficacy issues caused by formation of immune complexes.

The new bioanalysis kit is optimizsed for use on all Gyrolab systems and complements the company’s existing portfolio of ready-to-use kits and solutions for pharmacokinetics and toxicokinetics, while expanding the utility of the Gyrolab platform into drug screening and preclinical phases of development. Automation with Gyrolab systems reduces variability due to manual intervention and speeds up workflows by generating 96 data points within 80 minutes, helping to speed the development of novel therapeutics. Additionally, the Gyrolab platform supports the development of drug-specific ADA assays in the later stages of drug development, using automated acid dissociation in the Gyrolab Mixing CD 96 and the dedicated Gyrolab ADA Software, enabling immunogenicity assessment all the way from discovery to every phase of process development.

For more information: www.gyrosproteintechnologies.com/immunoassays/products/gyrolab-generic-cyno-ada-kit-reagents.

 

Upcoming Events

Participants’ Meeting: UK NEQAS Immunology, Immunochemistry & Allergy

Sheffield Hallam University, City Campus, Howard Street, Sheffield
24 May, 2024

Med-Tech Innovation Expo

NEC, Birmingham
5-6 June, 2024

UK NEQAS Blood Coagulation: Clinical and Laboratory Haemostasis 2024

Sheffield Hallam University
5-6 June, 2024

LabMedUK24

DoubleTree by Hilton Brighton Metropole
10-12 June, 2024

Infection Diagnostics Symposium 2024

IET Austin Court, Birmingham
26-27 June, 2024

SHOT Symposium 2024

Mercure Manchester Piccadilly Hotel
9 July, 2024

Access the latest issue of Pathology In Practice on your mobile device together with an archive of back issues.

Download the FREE Pathology In Practice app from your device's App store

Upcoming Events

Participants’ Meeting: UK NEQAS Immunology, Immunochemistry & Allergy

Sheffield Hallam University, City Campus, Howard Street, Sheffield
24 May, 2024

Med-Tech Innovation Expo

NEC, Birmingham
5-6 June, 2024

UK NEQAS Blood Coagulation: Clinical and Laboratory Haemostasis 2024

Sheffield Hallam University
5-6 June, 2024

LabMedUK24

DoubleTree by Hilton Brighton Metropole
10-12 June, 2024

Infection Diagnostics Symposium 2024

IET Austin Court, Birmingham
26-27 June, 2024

SHOT Symposium 2024

Mercure Manchester Piccadilly Hotel
9 July, 2024

Access the latest issue of Pathology In Practice on your mobile device together with an archive of back issues.

Download the FREE Pathology In Practice app from your device's App store

Step Communications Ltd, Step House, North Farm Road, Tunbridge Wells, Kent TN2 3DR
Tel: 01892 779999
www.step-communications.com
© 2024 Step Communications Ltd. Registered in England. Registration Number 3893025